Pfizer raises COVID-19 vaccine sales forecast to $36-B for 2021
Pfizer Inc on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in broader age groups.
Driven by an unprecedented vaccination drive against the COVID-19 pandemic globally, Pfizer's shot has quickly become one of the best-selling products in the company's roughly 172-year history. The company equally splits expenses and profit from the vaccine with its German partner BioNTech.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: